A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight
← catalyst calendarNCT07605052 · readout in 15 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
50estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-20 | actual | When the study began enrolling |
| Primary completion | 2026-09-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-03 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight
- Obesity
Interventions
- Drug: Cagrilintide B
- Drug: Cagrilintide D
Primary outcomes
what the primary-completion date above is the date OFAUCss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide
measured From Pre-dose at Day 29 to Day 36
Cmax,ss: maximum observed concentration of total cagrilintide at steady state after 5th dosing of cagrilintide
measured From Pre-dose at Day 29 to Day 36
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed